iSpecimen shares surge 16.36% premarket after completing private placement and engaging IR consulting firm.

iSpecimen Inc. surged 16.36% in premarket trading following insider buying activity and recent operational expansions. Benjamin Bielak, an insider, acquired 18,000 shares on September 16, signaling confidence in the company’s strategic direction. Additionally, iSpecimen announced on September 13 that it expanded its provider network to enhance support for women’s health research, a move likely to strengthen its market position and research partnerships. These developments, combined with recent cost-cutting measures and profitability initiatives, suggest a focus on operational efficiency and growth in key therapeutic areas, which may have driven investor optimism ahead of the market open.